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Constitutively active protein phosphatase 1a causes
Rb-dependent G1 arrest in human cancer cells 
Norbert Berndt, Mariam Dohadwala and Cathy W.Y. Liu 
Background: The retinoblastoma protein (Rb) needs to be phosphorylated by
cyclin-dependent kinases (CDKs) before mammalian cells can enter the S
phase of the cell cycle. As protein phosphatase 1 (PP1) activates Rb and is
itself a target for inhibitory phosphorylation by CDKs in vitro, we asked whether
any effects of PP1 on cell cycle progression depend on its phosphorylation and
are mediated through Rb. 
Results: Using electrotransfer of recombinant protein into Rb-positive and Rb-
negative cells, we have compared the effects of a wild-type PP1 catalytic
subunit, PP1a, and a constitutively active mutant of this subunit (PP1aT320A)
on G1 progression, proliferation rates, and cell viability. In treated cells, PP1a
levels were elevated 6–16-fold and remained stable for at least 48 hours. In Rb-
positive cells, PP1aT320A, but not PP1a, caused cell cycle arrest in late G1,
which was associated with a lack of Rb phosphorylation. In Rb-negative cells,
neither wild-type nor mutant phosphatase caused any change in cell cycle
progression. Increased cell death was observed in both Rb-positive and Rb-
negative cells, however, upon introduction of excess PP1a. 
Conclusions: The difference between the effects of wild-type and mutant forms
of PP1a suggests that PP1a has the potential to arrest cell growth in G1
unless it is inactivated by periodic phosphorylation at Thr320, presumably by
CDKs that regulate passage through the G1–S cell cycle transition. Together,
the effects in both cell types suggest that PP1a requires functional Rb to induce
growth arrest, and that possibly another pool of PP1a induces cell death. This
identifies PP1 as a potential target for therapeutic anti-proliferative strategies.
Background
The two major events of the eukaryotic cell cycle, DNA
replication (S phase) and cell division (M phase), are sepa-
rated by two gap phases, G1 and G2. During these gap
phases, a cell decides whether to proliferate, to withdraw
from the cell cycle, or to die; these decisions are made at
so-called checkpoints and attune a cell’s responses to
extracellular signals to its developmental status and/or the
demands of cellular homeostasis. Although these check-
points are poorly understood at the molecular level, it is
believed that both unrestrained growth and the multiple
genetic aberrations associated with malignant tumors are
due to loss or damage of the pathways that converge on
checkpoint controls [1–4]. 
In all eukaryotic cells, cell cycle progression is driven by
multiple phosphorylations of key regulatory proteins [5,6],
catalyzed by a family of Ser/Thr-specific protein kinases
termed cyclin-dependent kinases (CDKs; for recent
reviews, see [7–9]). CDKs are transiently activated by com-
plexing to cyclins and by a series of phosphorylation and
dephosphorylation reactions; different cyclin–CDK
complexes promote distinct phases of the cell cycle.
Understanding the regulation of how protein phosphatases
oppose the action of CDKs is important to fully appreciate
cell cycle control. The importance of phosphatase regula-
tion has a static and a dynamic aspect: first, at any one time,
the phosphorylation state of a given protein depends on the
ratio of protein kinase and phosphatase activities; second,
at times, dephosphorylation of CDK substrates may be
necessary to ensure an orderly cell cycle, whereas at other
times, dephosphorylation may allow for (temporary) halts. 
Mammalian Ser/Thr-specific protein phosphatases (PPs;
for recent reviews, see [10,11]) are represented by four dis-
tinct prototypes, PP1, PP2A, PP2B and PP2C [12]. The
idea that phosphatases may be involved in growth control
was generated when it was realized that a marine toxin,
okadaic acid, is a powerful tumor promoter [13] and a spe-
cific inhibitor of PP1 and PP2A [14]. These discoveries
have led to the suggestion that PP1 and PP2A might func-
tion as tumor suppressors in mammalian cells [15,16]. Sub-
sequent studies have indeed established roles for both PP1
and PP2A in cell growth regulation. Thus, genetic analysis
of Aspergillus nidulans and Schizosaccharomyces pombe
mutants has revealed that PP1 controls the completion of,
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or exit from, mitosis [17–20], whereas PP2A may inhibit
entry into mitosis [20]. These genetic data were biochemi-
cally confirmed for vertebrate cells: microinjection of PP1-
neutralizing antibodies into early mitotic cells arrests them
in metaphase [21]. 
Meanwhile, a variety of approaches has shown that PP2A
negatively regulates the mitosis-specific form of CDK1
[22–24], most likely by inactivating the tyrosine phos-
phatase Cdc25, an enzyme that participates in the activa-
tion of CDK1 [25,26]. Also, SV40 small tumor antigen
appears to induce cell proliferation by inhibiting PP2A
[27]. Equally interesting is the observation that PP2A can
be inactivated by a number of oncogenic protein tyrosine
kinases in vitro [28] and in vivo, suggesting another
pathway to transformation [29]. Most importantly, PP1
was identified as the most likely phosphatase to be
responsible for the activation of the retinoblastoma tumor
suppressor protein, Rb [30–33]. Rb is heavily phosphory-
lated, and thus inactivated, by CDKs in late G1, thereby
permitting cells to proceed into S phase (reviewed in
[34–36]). In summary, there appears to be sufficient evi-
dence supporting the hypothesis that PPs inhibit cell
growth. As there is, in mammalian cells, an important
checkpoint shortly before S phase (mediated by Rb, as
described), one would expect that this postulated function
of PPs is, at least partially, associated with the G1 phase of
the cell cycle. 
We have previously shown that CDKs phosphorylate and
inhibit PP1 in vitro, and have mapped the site of phos-
phorylation of the rabbit PP1a catalytic subunit (which
has an identical amino acid sequence to all other cloned
mammalian PP1a subunits, including the human isoform)
to Thr320 [37]. In addition, in human MG63 osteosarcoma
cells, PP1 activity oscillates in a cell-cycle-dependent
manner with peaks in G0/G1 (cytoplasmic and nuclear)
and G2/M (nuclear only); at the G1–S boundary and in S
phase, PP1 activity is suppressed to about 25% of the
maximum [37]. The cell-cycle-dependent activity profile
of PP1 is inversely related to the degree of Rb phosphory-
lation and the activity of some CDKs, especially those that
associate with G1-specific cyclins and/or cyclin A. Thus,
we speculated that at some point in G1 CDKs not only
inactivate Rb, but also inactivate PP1, in order to ensure
maximal phosphorylation of Rb [33]. A site equivalent to
Thr320 is apparently phosphorylated in vivo by the S.
pombe CDK, Cdc2 [38]. However, owing to the difficulties
associated with trapping phosphatases in their phosphory-
lated form [39], evidence for in vivo phosphorylation of
Thr320 in mammalian cells is still lacking. 
In order to examine the function of the PP1a catalytic
subunit in the cell cycle, as well as the potential role of the
postulated phosphorylation of PP1a by CDKs, we have
introduced recombinant wild-type PP1a and mutant PP1a
(PP1aT320A), which contains an alanine in place of threo-
nine at the CDK phosphorylation site at residue 320, into
electropermeabilized cells. The phosphorylation-resistant
mutant could arrest cells in late G1 and prevent Rb phos-
phorylation, yet wild-type PP1a was unable to arrest cell
growth and, accordingly, failed to alter the phosphoryla-
tion of Rb that normally occurs in cells approaching S
phase. As Rb-negative cells were not growth-inhibited by
either wild-type or mutant phosphatase, we conclude that
the ability of PP1a to arrest cell growth may indeed
depend on its phosphorylation state, and is mediated,
perhaps exclusively, by Rb. Furthermore, we will discuss
evidence suggesting that PP1 may induce cell death inde-
pendently of Rb. 
Results
Intact PP1a can be electrotransferred into MG63 cells
As PP1 is not readily overexpressed in mammalian cells,
we have adopted the electroporation technique [40] to
introduce recombinant PP1 into cells and study the role(s)
of PP1 in cell cycle progression. Increasing the voltage or
capacitance of electroporation increases the incorporation
of protein into cells, but decreases the cell viability, and
the extent of these changes is dependent on the cell type
[40]. Therefore, we determined the conditions represent-
ing the optimal compromise between these two parame-
ters for MG63 cells, the same cell line that was used in our
previous study [37]. As shown in Figure 1a, by varying the
voltage and capacitance between 120 and 280 V and 25
and 500 mF, respectively, uptake of exogenous bovine
serum albumin (BSA) increased from zero to nearly 6 mg
per 2 × 105 cells, establishing that MG63 cells incorporate
foreign protein in a predictable fashion. However, the via-
bility of cells dropped below 70% at capacitance settings
≥ 250 mF. Therefore, we defined optimal conditions —
those which had the highest protein uptake for a tolerable
recovery of surviving cells — as a voltage setting of 280 V
and a capacitance of 125 mF. 
Using these optimal conditions, we treated between
2 × 105 and 3.2 × 106 cells with a constant relative amount
of PP1a. Densitometric analysis of the band intensities
showed that approximately 22% of the PP1a protein
present in the electroporation buffer was recovered in
whole cell lysates (Fig. 1b). Next, we treated 1.6 × 106
cells with an increasing amount of PP1a (between 15 and
240 units per 106 cells), and measured the PP1 activity in
cytosolic lysates one hour after electroporation. The
amount of activity recovered in cytosolic lysates was pro-
portional to the amount used for electroporation: it varied
between 12.9% and 16% (14.8% on average) of the amount
used (Fig. 1c), thus being slightly lower than the fraction
of protein recovered in whole cells. This suggests that
more of the exogenous PP1a localized in the cytosol than
in the nuclear or membrane compartments. In summary,
the successful incorporation into cells of the active PP1a
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catalytic subunit indicated that electropermeabilization
could be used to study regulatory functions of PP1.
BSA and inactive PP1a do not halt cell cycle progression
Because of the elevated PP1 activity associated with the
G0/G1 phase [37] and the known interaction between Rb
and PP1 [30–33], our aim was to determine the role of
PP1a in the G1–S transition and whether this function
might be mediated through phosphorylation at Thr320. As
a first step, it was necessary to estimate the duration of the
G1 phase and the time of entry into S phase of cells
released from G0/G1. The cells were harvested at regular
intervals over a period of 24 hours and the percentage of
cells in different phases of the cell cycle was estimated by
flow cytometric analysis of the DNA content (Fig. 2a).
From 16 to 18 hours after release from G0, between 51%
and 67% of the cells originally in G0/G1 had exited from
G1; 22 hours after release from G0/G1, 89% of the cells
were found to be in S and G2/M phases. Moreover, at the
end of the observation period, the cells had not yet gone
through a division as the cell number had not increased in
comparison to controls at time zero. This control experi-
ment helped to design the experiments involving PP1a:
first, it determined the time frame during which a sizable
portion of cells was still in G1 and thus was suitable for
electroporation with PP1a; second, it established the time
after which most cells had exited from G1 — at this time
point any effect on the G1–S transition would become
most apparent. Thus, we took the median length of the
G1 phase as 18 hours, arbitrarily subdivided it into three
periods of 6 hours each, and designated them early, mid
and late G1; 22 hours appeared to be suitable to analyze
PP1 effects on cell cycle progression. 
We examined whether electroporation of cells with either
BSA or inactive PP1a affects cell cycle progression. PP1a
was made inactive by boiling or long-term storage. To
establish the starting conditions, sister cultures of identi-
cally treated cells were analyzed by flow cytometry at the
beginning of the experimental treatment — 3, 9 and
15 hours after release from G0 (Fig. 2b). Cells, harvested
by trypsinization, were then subjected to one of three dif-
ferent treatments and replated: control cells were just kept
on ice (Fig. 2c) while experimental cells were electropo-
rated with either BSA (Fig. 2d) or inactive PP1a (Fig. 2e).
All cells were analyzed by flow cytometry 22 hours after
release from G0. In the PP1a-treated cells, the band inten-
sity of PP1a on western blots was approximately 10 times
higher than that of endogenous PP1a (Fig. 2f). The rela-
tive inhibition of G1 exit by foreign protein was negligible:
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Figure 1
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Optimization of electroporation conditions for MG63 cells. (a)
Efficiency of protein incorporation and cell viability as a function of
increasing voltage and capacitance. Cells (8 × 105) were mixed with
1 mg of bovine serum albumin (BSA) in a volume of 200 ml and
electroporated at different combinations of voltage and capacitance.
Cells were replated in 25 cm2 flasks 15 min after the pulse, incubated
for 18 h, harvested, lysed with SDS sample buffer and subjected to gel
electrophoresis, with each lane containing sample equivalent to
2 × 105 cells. Lanes containing known amounts of BSA were used to
establish a linear relationship between the band intensities, after
Coomassie Blue R staining, and the mg amounts of BSA using the
Scanning Densitometer GS300 and the software program GS370
v3.0 (Hoefer). This calibration curve was then used to calculate BSA
uptake. To measure cell viability (shown as the mean of duplicate
experiments), small aliquots of cells were counted after mixing with
trypan blue; control cells were carried through the same manipulations
as the experimental ones except that they were not electroporated. The
recovery of viable cells in these controls was 85%. (b) Uptake of PP1a
protein into MG63 cells. Either (lane 1) 1.2 × 106 MG63 cells alone or
(lane 2) 4 × 105 cells mixed with an excess of exogenous PP1a (60 U,
or approximately 3 mg, per 106 cells) were electroporated under the
optimal conditions determined in (a): 280 V and 125 mF. One hour
after electroporation, portions of the cells were lysed in SDS sample
buffer. Proteins were separated by gel electrophoresis and stained
using Coomassie Blue R. Molecular weight standards (lane 3), and
(lane 4) 15 U of purified PP1a (approximately 0.75 mg) — the amount
used to treat the cells in lane 2 — were also separated by gel
electrophoresis. (c) Recovery of PP1 activity after electroporation.
Cells (1.6 × 106) were electroporated as in (b) in the presence of
increasing amounts of PP1a; 1 h after electroporation, cells were lysed
in buffer A and assayed for PP1 activity. Values are the mean of two
independent experiments.
it was calculated to be ≤ 12.8% for BSA and ≤ 12.9% for
inactive PP1a. This demonstrates that the presence of
inactive PP1a alone did not hinder cell cycle progression
any more than electroporation per se or the presence of
BSA. Therefore, in the experiments described below, BSA
treatment was used as a reference. 
PP1a activity delays cell cycle progression in G1
When MG63 cells were electroporated and analyzed in a
way analogous to that described above, it became apparent
that recombinant wild-type PP1a and PP1aT320A had dif-
ferent effects on cell cycle progression. A representative
experiment is shown in Figure 3a–d. When transferred into
cells in early G1, both wild-type and mutant PP1a effec-
tively inhibited progression into S phase: the proportion of
cells in G1 remained virtually constant over a 19 hour
period. When transferred into cells in mid G1, the ability of
wild-type PP1a to inhibit progression into S phase
decreased almost two-fold when compared with the effect
in early G1. In late G1, wild-type PP1a was unable to
prevent cells from entering S phase, as indicated by the
fact that, 7 hours later, the G1 fraction was as low as in
BSA-treated controls. In contrast, mutant PP1a continued
to inhibit cell cycle progression in mid and late G1 with
similar effectiveness: the ratio of G1 cells at 22 hours to G1
cells before electroporation remained virtually unchanged
at all three time points. Figure 3e summarizes the results
from three experiments and shows the calculated relative
inhibition of G1 exit.
In order to verify the levels of phosphatase, we deter-
mined the activity (Fig. 3f) and protein amounts (Fig. 3g)
in cell lysates after completing the treatment: for both
species of PP1a, the activity was between 11-fold and 16-
fold higher than the endogenous levels, and the protein
levels were similarly elevated. The PP1a and PP1aT320A
bands were analyzed densitometrically, and the ratios of
PP1a:BSA and PP1aT320A:BSA were similar at the end
of the 19, 13 and 7 hour treatment periods (data not
shown), demonstrating that the incorporated phosphatase
was stable for at least 19 hours. The results of these exper-
iments strongly suggest that the delay in G1 progression
was due to PP1 activity and not to the mere binding of
PP1 to other cellular proteins, as PP1 without enzyme
activity had no such effect. 
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Figure 2
Effect of electroporation with BSA or inactive PP1a on cell cycle
progression. (a) Normal cell cycle progression of MG63 cells. Cells
(1 × 106) were plated in 75 cm2 flasks and rendered quiescent as
described in Materials and methods. At the indicated times, cells were
harvested and their cell cycle distribution was analyzed by flow
cytometry. The error bars indicate the standard deviation (n = 3). (b)
For reference, cells were synchronized in, and released from, G0,
collected at 3 h (early G1), 9 h (mid G1) and 15 h (late G1), and then
analyzed by flow cytometry. Experimental cells were treated as follows:
for each flow cytometry profile shown, 2 × 106 cells were collected by
trypsinization at 3, 9 or 15 h, washed, and either (c) kept on ice for
30–40 min, (d) electroporated with 100 mg BSA or (e) electroporated
with 20 mg inactive PP1a protein. All cells were replated at 1 × 106
cells per 75 cm2, and incubated at 37°C. At 22 h, cells were harvested
to perform flow cytometric analysis of the DNA. (f) The PP1a
preparation used in (e) had been stored for two years at –20°C and
was virtually inactive, yet intact, as inactive PP1a (PP1-I) co-migrated
with endogenous PP1a (marked with an arrow) in a western blot of
whole-cell lysates of cells electroporated with either BSA or PP1-I (as
labeled). The blot contained lysate from 5 × 104 cells per lane and was
probed with an antipeptide antibody to the carboxyl terminus of PP1a
[58]. Another experiment, in which PP1a was inactivated by boiling,
produced essentially the same results. 
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Mutant PP1a prevents the G1–S transition and Rb
phosphorylation in late G1
It is well established that the dephosphorylated form of
Rb is associated with the G0/G1 phase and that Rb phos-
phorylation is required to permit passage from G1 to S
phase [34–36]. Moreover, evidence has accumulated to
suggest that Rb is dephosphorylated by PP1 in vivo
[30–33]. To identify a possible mechanism of action for
the PP1a-induced cell cycle effects, we examined the
phosphorylation state of Rb in cells electroporated with
PP1a. To that end, we synchronized MG63 cells in late
G1 with mimosine [41], removed the arresting drug and
electroporated the cells with wild-type or mutant PP1a.
Six hours later, one half of the cells was harvested to assess
the DNA content by flow cytometry (Fig. 4a). The other
half of the cells was labeled with [32P]inorganic phosphate
(32Pi) for 2.5 hours, 3.5 hours after replating, and then har-
vested. Rb was immunoprecipitated, separated by gel
electrophoresis and visualized by autoradiography (Fig.
4b); as before, PP1a band intensities in treated cells were
significantly higher than the endogenous levels (Fig. 4c).
Control cells were 32P-labeled or analyzed by flow cytome-
try before release from mimosine arrest. 
At time zero, the cell population was almost exclusively in
G1 (Fig. 4a, 0 h), and the Rb protein was largely under-
phosphorylated (Fig. 4b, 0 h). Six hours later, the majority
of control cells had proceeded into S phase (Fig. 4a,
6 h + BSA); accordingly Rb was, as expected, heavily
phosphorylated (Fig. 4b, 6 h + BSA). In response to wild-
type PP1a, cells advanced into S phase unperturbed (Fig.
4a, 6 h + PP1a), and Rb was phosphorylated to a similar
level as in control cells (Fig. 4b, 6 h + PP1a). However,
cells treated with PP1aT320A remained mostly in G1
(Fig. 4a, 6 h + T320A), and phosphorylation of Rb appar-
ently did not increase beyond the levels seen at the begin-
ning of the experiment (Fig. 4b, compare 0 h to
6 h + T320A). This experiment, performed with a cell
population that was synchronized in late G1, confirmed
the earlier observation that PP1aT320A, but not PP1a,
blocks the G1–S transition. 
Constitutively active PP1 causes cell growth arrest and cell
death
The remarkable stability of PP1a electroporated into
cells, as well as the ability of the electropermeabilized
cells to proceed normally through the cell cycle, indicated
that it was feasible to explore potential effects of PP1 on
cell proliferation by electrotransfer. The inhibition of S-
phase entry by PP1aT320A could represent either a mere
lengthening of the G1 phase or a cell cycle arrest. To dis-
tinguish between these two possibilities, we carried out an
experiment over a longer period of time: we introduced
wild-type PP1a or the phosphorylation-resistant mutant
PP1aT320A into a growing, asynchronous cell population,
replated the cells at 2 × 105 cells per 75 cm2 and recorded
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Figure 3
PP1a inhibits G1 progression in MG63 cells.
(a–d) The experiment was performed and the
data are presented in the same manner as for
Figure 2b–e, except that either (b) BSA or
(c,d) active enzyme (100 U of either (c) wild-
type or (d) mutant PP1a) was electroporated
into cells. This experiment was carried out
three times with two different PP1a and
PP1aT320A preparations each, and the data
from these three experiments, indicating the
percentage of cells in different phases of the
cell cycle, were used to calculate (e) the
degree of inhibition of exit from G1 by PP1a
relative to BSA. (f) PP1 activity and (g) PP1a
protein in cytosolic lysates of cells,
electroporated as in (b–d), harvested 22 h
after release from G0. The enzyme activity
was assayed in diluted lysates in the presence
of 2 nM okadaic acid with
[32P]phosphorylase a as a substrate. In (g),
the anti-PP1a antibody FL-18 was used to
probe the western blot, with each lane
containing lysate from 1 × 105 cells. In (e) and
(f), the error bars indicate the standard
deviation (n = 3).
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the cell number, cell viability, level of PP1 activity, and
amount of PP1a protein, every 24 hours for 4 days. 
Phosphatase-treated cells did not display any obvious
changes in morphology when compared to either
untreated or BSA-treated cells; the vast majority of the
cells appeared fully attached and flattened out, suggesting
that these cells were predominantly in G1 (data not
shown). As shown in Figure 5a, during the first two days,
cells treated with wild-type PP1a increased in number by
1.2-fold and 1.4-fold, respectively; over the same period,
control cells grew more rapidly — 1.7-fold and 2.2-fold.
However, during the third and fourth day after replating,
the relative increase in cell number of cells treated with
PP1a was very similar to that of controls. In contrast, cells
treated with the mutant PP1aT320A did not grow at all
during the first three days, yet resumed to proliferate
during the fourth day, at essentially the same rate
(1.9-fold) as control cells (2.2-fold). Growth inhibition or
lack of growth was also observed when cells were plated at
8 × 105 cells per 75 cm2 (data not shown), indicating that
the observed effects were independent of cell density. As
in previously described experiments, the magnitude of the
effects suggest that PP1a had been incorporated into the
vast majority of cells. 
Interestingly, cells treated with mutant PP1a appeared to
die more frequently: immediately after electroporation,
approximately 15% of the cells were positive for trypan
blue in all four cell populations (Fig. 5b). One day later,
untreated controls and cells treated with BSA or wild-type
PP1a had apparently recovered, while the PP1aT320A
mutant significantly increased both the number and
proportion of dead cells (Fig. 5b). The basis for this
finding will have to be investigated further (see Discus-
sion). Treatment with inactive PP1a protein had no effect
on either proliferation or cell viability (data not shown). 
As expected, the growth inhibition or arrest was associated
with elevated PP1 activity in cytosolic lysates (Fig. 5c) and
higher protein amounts (Fig. 5d) for both wild-type and
mutant PP1a. Until day three, the activity and protein
levels in cells treated with PP1aT320A remained virtually
constant (between 6-fold and 8-fold higher than in BSA
controls), yet dropped significantly on day four. The activ-
ity measured in cells treated with wild-type PP1a was ini-
tially elevated to similar levels (7-fold increase over basal
level) as those in mutant-treated cells, but decreased more
rapidly than in these cells, and was virtually identical to
the basal levels on the fourth day. For wild-type PP1a, the
loss of activity (expressed in units per 106 cells) over time
occurred more rapidly than the decrease in protein that
could be seen in western blots in which each lane contains
lysates of equal numbers of cells (Fig. 5d). These results
demonstrate that both wild-type and mutant PP1a protein
remained essentially stable for 48 to 72 hours. The
endogenous activity levels measured in cells released from
G0 (for example, those shown in Fig. 3f) were noticeably
lower than those measured in this experiment, in which
asynchronous cells mostly in G1 were used. As the former
cells were enriched in S or G2/M phase (see Fig. 3a), this
finding was in keeping with our previous observation that
cytosolic PP1 activity is suppressed during S and G2/M
phases [37]. In similar experiments with the leukemia-
derived, p53-negative HL60 cell line, the two PP1a species
also induced growth inhibition or arrest (data not shown).
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Figure 4
Constitutively active PP1a prevents the G1–S
transition and phosphorylation of Rb in MG63
cells. Cells (2 × 106) that had been
synchronized by mimosine blockade (see
Materials and methods), were either used
before lifting the G1 arrest (0 h) or washed
extensively to remove the drug, and
electroporated with 100 mg BSA, 100 U wild-
type PP1a, or 100 U PP1aT320A, replated
(1 × 106 cells) in duplicate and harvested 6 h
later (6 h + BSA, 6 h + PP1a, and
6 h + T320A, respectively). (a) One set of
samples was used for flow cytometry and (b)
another was 32Pi-labeled and used to analyze
the Rb phosphorylation state and PP1a
content. To ensure loading of comparable
samples in adjacent lanes, small aliquots of
the pre-cleared lysates were separated
electrophoretically and the band intensities in
each lane were used to compute the relative
protein amount in each lysate so that
equivalent amounts of the Rb
immunoprecipitates could be separated on an
8% polyacrylamide gel. The gel was dried and
exposed to Kodak X-Omat AR film for 24 h.
(c) Aliquots of the same lysates, containing
equal amounts of protein, were used to
perform western blots using anti-Ca.
(a) (b)
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In summary, our experiments indicate that PP1aT320A
could induce growth arrest in serum-depleted or growing
cells; therefore, this effect did not depend on whether the
cells had to pass through G0 and G1 or only G1 to enter S
phase. Secondly, it is worth noting that the effects on cell
growth were reversible: they no longer persisted as soon as
the excess activity had dropped to a level approximately
4-fold above the endogenous activity in BSA-treated cells. 
PP1a-induced growth arrest, but not cell death, depends
on functional Rb
To determine whether Rb is a major, if not the only,
target capable of mediating the growth arrest induced by
PP1a, we examined whether PP1a affects the growth
properties of Saos2 cells, which have widely been used to
study the consequences of Rb loss (see [42,43] for
example). As Saos2 cells were found to traverse the cell
cycle much more slowly than MG63 cells (data not
shown), we chose different time points for analysis in the
next two experiments. An experiment that was designed
similarly to the one presented in Figure 4 demonstrates
that an excess of either wild-type or mutant PP1a was
unable to prevent the transition from G1 to S phase in
Saos2 cells (Fig. 6a). The fact that adding mimosine to a
population of control cells could keep most of them in a
G1 arrest (Fig. 6a, 18 h + mim) demonstrates that the lack
of effect of PP1a was not due to a general failure of these
cells to be arrested at this point. Following electroporation
of growing, asynchronous cells with phosphatase, the rela-
tive growth rates were very similar to controls (except for
day one, see below), indicating that neither form of PP1a
could induce cell growth arrest in Saos2 cells (Fig. 6c). As
with MG63 cells, we observed increased numbers of
trypan-blue positive cells following electroporation;
whereas the BSA-treated control cells recovered from this
damage during the first 2 days, both phosphatase-treated
cell populations sustained massive cell death during the
first 24 hours (Fig. 6d). This, and not cell growth arrest, is
the most likely explanation for the substantially decreased
cell number of phosphatase-treated cells that persisted
throughout the observation period (Fig. 6c). 
Discussion
Role of PP1a in the G1 phase of the cell cycle 
In this study, we have examined potential role(s) of PP1a
in cell growth control by introducing recombinant protein
into human Rb-positive and Rb-negative osteosarcoma
cells. The main results of this paper are as follows. In Rb-
positive cells, elevated levels of PP1a negatively affected
G1 progression and cell proliferation. At the same time,
the effects of a mutant PP1a that lacks the CDK phos-
phorylation site Thr320 markedly differed from those of
wild-type PP1a. The Thr→Ala mutant cannot be inhib-
ited by phosphorylation at this site [37], whether by
CDKs or any other protein kinase, and is therefore consti-
tutively active. This mutant effectively prevented the
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Figure 5
PP1a inhibits the proliferation of MG63 cells. Cells (2 × 106) were
electroporated with 100 mg BSA, 100 units wild-type PP1a or
100 units PP1aT320A as described in Materials and methods, and
then replated at a density of 2 × 105 cells per 75 cm2. (a) Cell number
per plate and (b) cell death are shown over a period of four days after
electroporation with the indicated protein; untreated control cells were
processed as were the experimental cells except that they were not
electroporated. (c) PP1 activity and (d) amounts of PP1a in lysates
from electroporated cells. (a–c) This experiment was carried out four
times, using two different preparations of either PP1a or PP1aT320A;
the error bars indicate standard deviation (n = 4). (d) The western blot
was developed with anti-Ca, and the volumes loaded in each lane
corresponded to 1 × 105 cells.
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G1–S transition, thus causing cell growth arrest, whereas
wild-type PP1a merely protracted the G1 phase leading
to a lower growth rate. A molecular framework for these
effects is provided by the observation that, shortly before
S-phase entry, the PP1aT320A mutant kept Rb in a
dephosphorylated state, whereas wild-type PP1a did not
prevent the Rb phosphorylation that normally occurs at
this point. In Rb-negative cells, neither wild-type PP1a
nor PP1aT320A affected the G1–S transition or the prolif-
eration rate of the cells, which suggests that the growth-
suppressing potential of PP1a requires the presence of
functional Rb. The same has been reported for the CDK
inhibitor p16INK [43,44]. Although we have observed
nearly identical results in two different Rb-positive cell
lines, further studies will be needed to determine whether
PP1a-induced cell cycle arrest functions universally in
mammalian cells or is, perhaps, developmentally regulated.
The differential effects of wild-type and mutant PP1a
support the hypothesis that phosphorylation at Thr320 of
the protein plays a key role in the G1–S transition of the
mammalian cell cycle. The enzyme activity in cells
treated with wild-type PP1a, however, was only slightly
smaller than that in mutant-PP1a-treated cells. This sug-
gests that only a minor portion of PP1a is subject to phos-
phorylation at Thr320, which may not be surprising given
that the PP1a enzyme system is believed to play multiple
roles in cells [10,11,33]. Direct proof that PP1a is being
phosphorylated in vivo in a cell-cycle-dependent manner
was not obtainable at this time, as an antibody capable of
immunoprecipitating the phosphorylated form of PP1a
was not available to us. 
Bearing in mind that cell cycle regulatory mechanisms are
highly conserved throughout the eukaryotic world, regula-
tion of PP1 by CDK phosphorylation in mammalian cells
appears to be very likely because the S. pombe homolog of
PP1, Dis2, is inhibited in vitro through phosphorylation at
Thr316 (which corresponds to Thr320 in mammalian PP1a)
by Cdc2 [38], and becomes phosphorylated at the onset of
M phase [45]. Interestingly, overexpression of the mutant
dis2T316A greatly inhibited cell division in S. pombe [38].
On the basis of these findings, it was suggested that PP1
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Figure 6
PP1a does not inhibit the G1–S transition or proliferation in Saos2
cells. As Saos2 cells were more susceptible to damage and took a
longer time to re-attach when electroporated under the same
conditions as MG63 cells, the voltage was reduced to 200 V, and the
cells were replated in gelatin-coated flasks. Cells (2 × 106) were
electroporated as before, except that the amount of PP1a used was
increased to 300 U. (a) Flow cytometric analyses of late G1-arrested
cells (0 h), cells after release from the late G1 block (18 h) or after re-
addition of mimosine (18 h + mim), and mimosine-released cells
following electroporation with BSA (18 h + BSA), wild-type PP1a
(18 h + PP1a) or mutant PP1a (18 h + T320A). (b) For each time
point, whole cell lysates were immunoblotted with anti-Ca. Each lane
contained protein equivalent to 5 × 104 cells. (c) Cell number per plate,
(d) cell death and (e) PP1a protein amounts are shown over a period
of six days after electroporation with the indicated proteins. Because of
the slow growth rate, the cells were replated at 4 × 105 cells per
75 cm2. PP1 enzyme activity was initially elevated 10-fold to 12-fold
and then slowly decreased to endogenous levels, which are similar
results to those obtained with MG63 cells.
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inactivation may be necessary for entry into mitosis,
whereas restoration of activity may be required for exit from
mitosis [38]. Our findings suggest that, in mammalian cells,
a somewhat similar mechanism may pertain to the transition
from G1 to S phase. Given that S. pombe has a very short G1
phase and therefore grows in length in G2, whereas mam-
malian cells are thought to make the important decisions
concerning proliferation in G0/G1 [1–4], a mechanism
implicating PP1 in the control of entry into S phase may be
useful for mammalian cells. 
A possible connection between phosphatase activity, the
phosphorylation state of Rb, the G1–S transition and/or
cell growth regulation has been suggested by previous
studies in different systems. That a phosphatase must be
important in regulating Rb function could be inferred
from the fact that only the dephosphorylated form of Rb
has growth-suppressing activity [42,46]. Furthermore, the
growth arrest induced by transforming growth factor b1 is
associated with a lack of Rb phosphorylation [47,48] and
rapid activation of PP1 [49]; whether these observations
are causally related is not clear, but became more plausi-
ble after several laboratories, including our own, identi-
fied PP1 as an Rb phosphatase [30–33]. The lack of Rb
phosphorylation that we saw in response to PP1aT320A,
was possibly due to two effects, either alone or in combi-
nation: direct dephosphorylation of Rb by the phos-
phatase, or interference with pathways that activate the
Rb kinases CDK4/6 and/or CDK2. The ability of wild-
type PP1a to delay G1 progression also depended on
functional Rb. From our earlier observation that short-
term inhibition of PP1 promotes Rb phosphorylation in
G0/G1, we speculated that PP1 activity is required to
keep Rb in a dephosphorylated state [33]. These new
results suggest that a gross imbalance in favor of the Rb
phosphatase PP1 is sufficient to keep Rb locked in a
dephosphorylated state. This may be due either to PP1
acting on Rb directly or to indirect effects, such as PP1a
reducing CDK promoter activity [50]. Eventually,
however, exogenous PP1 might not be able to escape its
inactivation, thus explaining its failure to induce growth
arrest. 
Our results differ in one aspect from one of the studies
identifying PP1 as an Rb phosphatase: microinjection of
purified PP1 into rat REF-52 fibroblasts renders Rb resis-
tant to extraction from the nucleus (which was interpreted
as a sign of underphosphorylation), and inhibits DNA syn-
thesis for a period of 6 hours [31]. In contrast to our
results, these effects were only seen when the enzyme
was injected just before S phase, but not earlier in G1.
Possible reasons for the discrepancy between these find-
ings and our own results are that, in REF-52 cells, the
enzyme becomes phosphorylated earlier in G1 phase or, as
the authors discussed, PP1 may be less stable in REF-52
cells than our data would suggest for MG63 cells. 
Finally, our study may offer a new explanation for the dif-
ficulties encountered by laboratories trying to overexpress
PP1 in mammalian cells. It has been assumed that this dif-
ficulty is mainly due to PP1 being grossly toxic to cells, to
the failure of PP1 to fold correctly, and/or to the require-
ment for a second protein that can act as a molecular chap-
erone. Our results suggest that excess free PP1 catalytic
subunit, when active, can play a pivotal role in mammalian
cells. It was shown by Fernandez et al. [51] that microin-
jected PP1 leads to a transient disassembly of the actin
microfilament network that last for up to 90 minutes. In
our experiments, which spanned time periods of no less
than 7 hours, we have not observed any gross effects of
increased PP1a levels on cellular morphology or survival.
Thus, no effects on the actin microfilament structure were
seen when we stained treated MG63 cells with rho-
damine–phalloidin every 24 hours (data not shown). In
any case, future attempts to establish a functioning PP1
expression system may have to take into account the fact
that PP1 is growth-suppressing. Therefore, successful
expression of PP1 has probably to await a reliable, tightly
regulated inducible promoter, because any expression
during the selection period or longer-lasting contamina-
tion of PP1-expressing cells with non-transfected cells will
make more difficult the generation of a PP1-expressing
cell population that is sufficiently large for analysis. 
The fact that the PP1a-induced growth inhibition was
reversible, even with the phosphorylation-resistant
mutant, would further argue against a generalized toxic
effect of PP1. In this context, it is important to note that
PP1a and PP1g1 were found to be overexpressed in a
variety of human tumors, which was taken as evidence for
a positive role of PP1 in tumorigenesis [52–54]. Our
results suggest a different scenario: PP1 may be over-
expressed in certain tumors to prevent a more rapid
growth. Obviously, it will be important to determine how
deletion of PP1 activity affects cell growth. 
PP1a and cell death
In Rb-positive cells, the mutant PP1aT320A appeared to
activate Rb and cause cell cycle arrest and/or cell death.
Although we have not yet carried out stringent assays
establishing apoptosis, these results are in agreement with
two recent reports that have addressed the possible
involvement of PP1 in apoptosis by using different
approaches. First, Dou et al. [55] showed that treatment of
p53-negative HL-60 cells with the anti-cancer drug cyto-
sine arabinoside induces Rb phosphatase activity, G1
arrest and eventually apoptosis. Although in that study no
attempt had been made to identify the protein phos-
phatase in question, several studies have, as already
pointed out, implicated PP1 in the dephosphorylation of
Rb [30–33]. Furthermore, on the basis of evidence
obtained with phosphatase inhibitors, Morana et al. [56]
have shown that PP1 can activate apoptosis. In the latter
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study, in several models of apoptosis examined, the Rb
protein was also dephosphorylated and cells were in S
phase when undergoing cell death; it was thus assumed
that phosphorylation of Rb during S phase prevents apop-
tosis [56]. Our results are consistent with this plausible
scenario.
The fact that PP1a could apparently induce cell death in
Saos2 cells suggests that there may be another pathway to
apoptosis that involves the dephosphorylation of one or
several proteins other than Rb. Both wild-type PP1a and
PP1aT320A led to a similar increase in cell death, sug-
gesting that another pool of PP1, not susceptible to CDK
phosphorylation, is involved in this process, which again
(see above) is consistent with the model of multiple roles
for individual phosphatases. 
Conclusions 
To our knowledge, this study represents the first demon-
stration that a PP1 catalytic subunit has the potential to
cause mammalian cell cycle arrest. This potential was
apparently dependent on the induction of sustained
dephosphorylation of functional Rb and on the presence
of an Ala residue at position 320 of PP1a which elimi-
nates a CDK phosphorylation site. These findings
suggest that PP1a is being periodically inactivated
through phosphorylation at Thr320, most probably by
CDKs that regulate passage from mid/late G1 to S phase,
thereby relieving a block preventing S-phase entry. Inac-
tivation of PP1, either by phosphorylation and/or other
mechanisms, may be required to permit entry of cells into
S phase. Further experiments will be needed to address
this hypothesis. In addition, we found that PP1a was able
to induce cell death, regardless of the Rb status of cells.
Although the exact mechanism underlying this latter
finding remains to be determined, together, our results
should be encouraging enough to prompt an exploration
of whether activating the PP1 pathway may be exploited
in tumor therapy. 
Material and methods
Cells, chemicals and proteins
Human osteosarcoma cells (MG63 and Saos2) and leukemia cells
(HL60) were obtained from the ATCC and grown in RPMI-1640 or
DMEM cell culture medium, respectively (Irvine Scientific). Fetal bovine
serum (FBS) was purchased from Gibco-BRL, phenylmethylsulfonyl flu-
oride (PMSF) from Pierce, g-[32P]ATP and 32Pi from ICN, chromatogra-
phy media, the E. coli expression vector pDR540 and
Protein-A-Sepharose Fast Flow from Pharmacia, okadaic acid from LC
Laboratories, and all other chemicals from Sigma unless otherwise
stated. Wild-type PP1a and PP1aT320A were expressed in E. coli and
purified as previously described [37,57]. The final preparations were
stored at –20°C in 20 mM Tris/Cl pH 7.5, 0.1 mM EDTA, 0.1 mM
EGTA, 0.1% (v/v) 2-mercaptoethanol, 50% (v/v) glycerol. Phosphory-
lase b and phosphorylase kinase were kindly provided by B.S. Khatra,
California State University. Antipeptide antibodies specific for the a-
isoform of PP1 (anti-Ca) were prepared as described [58]. Antibodies
to the intact PP1 catalytic subunit (FL-18) and antibodies to human Rb
(C-15) were obtained from Santa Cruz Biotechnology.
Electrotransfer of PP1 into cells
Subconfluent cells were washed twice with serum-free medium,
trypsinized, collected in a 15 ml tube and centrifuged at low speed for
8 min. Cells were resuspended and washed twice in medium. An
aliquot of the cell suspension was diluted 1:2 with 0.4% trypan blue
and counted with a hemacytometer. Cells were only used for electropo-
ration if the viability exceeded 95%. We optimized the electrotransfer
of PP1 into MG63 cells following the guidelines described by Wilson
et al. [40]. Typically, 1–2 × 106 cells were transferred to a electro-
cuvette with a 0.4 cm electrode gap and mixed with purified PP1
diluted in medium; the final volume was adjusted to 100–200 ml; the
control protein, BSA, was dissolved in the same buffer as PP1 [57].
This suspension was incubated for 10 min on ice. Using the gene
pulser plus capacitance extender (Bio-Rad), the cells were subjected
to a pulse of 280 V (MG63) or 200 V (Saos2 and HL60) at a capaci-
tance of 125 mF (MG63 and Saos2) or 250 mF (HL60), and a resis-
tance setting to ∞. Under these conditions, the time constant turned
out to be between 15 and 45 msec. After the pulse, the cells were
incubated for another 10 min on ice, and then slowly diluted with
medium containing 10% FBS that was kept at 37°C. After measuring
the viability of the electroporated cells, the cells were replated at a pre-
determined density and cultured for up to four days. 
Cell synchronization and metabolic labeling with 32Pi
To obtain MG63 cells in G0, 1 × 106 cells were cultured in 75 cm2
flasks in RPMI-1640 medium containing 0.5% FBS for 48 h [37,59].
Medium containing 10% FBS was then added to the cells to stimulate
re-entry into the cell cycle. To obtain MG63 or Saos2 cells arrested in
late G1, serum-deprived cells were incubated for a further 24 h in the
presence of 10% FBS and 600 mM mimosine [41]. For metabolic
labeling, cells were first incubated for 30 min with 2 ml phosphate-free
medium containing 5% FBS that had been dialyzed against phosphate-
free medium, and then labeled with 32Pi (1.2 mCi per 106 cells) for 2.5 h.
Flow cytometry
To monitor the cellular synchrony, at least 1 × 106 cells were harvested,
washed with Hanks’ balanced salt solution and fixed in 5 ml ice-cold
70% (v/v) ethanol. The cells were washed in phosphate-buffered saline
(PBS) and incubated in the presence of 40 mg ml–1 RNase A for
30 min at 37°C. After washing the cells with PBS, propidium iodide
was added to a final concentration of 40 mg ml–1. The DNA profiles
were examined with a FACScan flow cytometer using the program
CellQuest (Becton-Dickinson) [60,61]. To estimate the proportion of
cells in G0/G1, S and G2/M phases, the histograms were analyzed
with the ModFit program (Verity Software). 
Preparation of cell lysates 
After phosphate labeling, the radioactive medium was discarded and
the cells washed three times with serum-free medium. The cells were
lysed in the flask with 1.2 ml ice-cold RIPA buffer (50 mM Tris/Cl
pH 7.5, 0.1 mM EDTA, 150 mM NaCl, 1% (v/v) NP-40, 0.1% (w/v)
SDS) supplemented with freshly added protease, protein kinase and
protein phosphatase inhibitors: 0.5 mM EDTA, 0.1 mM PMSF, 1 mM
benzamidine, 1 mg ml–1 pepstatin A, 0.5 mg ml–1 leupeptin, 2 mg ml–1
aprotinin, 100 mM NaF, 1 mM Na3VO4 and 5 mM okadaic acid. 
In all other experiments, following treatment and incubation for various
periods of time, the cells were trypsinized, washed in serum-free
medium and collected by low-speed centrifugation for 8 min. An aliquot
of the cellular suspension was diluted two-fold with 0.4% trypan blue
and counted with the aid of a hemacytometer. Cellular suspensions
were then divided into several aliquots for different analyses: first, to
measure enzyme activity, cells were lysed with buffer A (50 mM Tris/Cl
pH 7.5, 150 mM NaCl, 1% (v/v) NP-40, 0.1 mM EDTA, 0.1 mM EGTA)
plus freshly added protease inhibitors and 0.1% (v/v) 2-mercap-
toethanol; second, for western blots of PP1a, cells were lysed with
RIPA buffer; and third, for straight electrophoretic analyses, cells were
lysed with boiling 2× concentrated SDS sample buffer (0.125 M
Tris/Cl pH 6.8, 4% SDS, 20% glycerol, 10% (v/v) 2-mercaptoethanol,
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0.05% bromophenol blue). The DNA was sheared by passing the
sample repeatedly through a 21-gauge needle. All lysates were cleared
by high speed centrifugation (3 min at 16 000 g).
Protein phosphatase assays 
PP1 activity was determined according to standard procedures
[62–64] as previously described [37]. Diluted samples containing PP1
were incubated in the presence of 10.2 mM [32P]phosphorylase a
(1 mg ml–1) and 2 nM okadaic acid to selectively inhibit PP2A. One unit
(U) of activity is defined as the amount that catalyzes the release of
1 nmol Pi from phosphorylase a per min at 30°C.
Immunoprecipitation of Rb from 32P-labeled cells 
Cell lysates were pre-cleared by adding 1 mg of anti-rabbit IgG and
30 ml of protein-A-Sepharose (containing 1 vol beads and 1 vol RIPA
buffer), followed by incubation for 30 min on ice. The beads were col-
lected by centrifugation for 4 min at 1500 g at 4°C. The supernatants
containing up to 2 × 106 lysed cells were incubated with 1.5 mg anti-
Rb antibody for 90 min on ice. Then 30 ml protein-A-Sepharose was
added to the lysates and incubated for 2 h with slow end-over-end
rotation at 4°C. The beads were centrifuged for 4 min at 1500 g at
4°C. After aspiration of the supernatant with a 25-gauge needle, the
beads were resuspended in a modified RIPA buffer (50 mM Tris/Cl
pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 100 mM NaCl, 1% (v/v) NP-40,
0.1% (w/v) SDS) containing freshly added protease inhibitors. The
beads were centrifuged as before and washed three more times. The
beads containing the immune complexes were then mixed with 40 ml of
2× concentrated SDS sample buffer and boiled for 5 min.
Gel electrophoresis and western blotting 
Whole cell lysates or immunoprecipitated protein were analyzed by
SDS-polyacrylamide gel electrophoresis [65] on pre-cast tris-glycine
gels from Novex and, if necessary, electrotransferred to Immobilon-P
membranes (Millipore) [66]. Samples in adjacent lanes corresponded
to either equal number of cells or, in the case of 32P-labeled cells, equal
amounts of protein. Membranes were probed for 2 h with anti-Ca
(1 mg ml–1) [67] and then incubated for 1 h with 50 ng ml–1 anti-rabbit
IgG conjugated to horseradish peroxidase (Kirkegaard & Perry Labora-
tories). Immunoreactive proteins were visualized with the ECL system
from Amersham according to the manufacturer’s instructions. 
Note added in proof
After revision of this manuscript, a paper by Kwon et al. (Proc Natl Acad Sci
USA 94:2168–2173) reported mitotic phosphorylation of mammalian PP1a
at Thr320. Recent experiments in our laboratory suggest that Thr320 of
PP1a is phosphorylated at two points during the cell cycle: first, from late
G1 through to early S phase (as postulated in this study); and second, from
G2 through to early M phase.
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